Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hospital-Acquired Anemia Affects One-Third of Patients

By LabMedica International staff writers
Posted on 31 May 2017
One in three patients hospitalized for medical problems experience hospital-acquired anemia (HAA), a drop in hematocrit due to the hospitalization, claims a new study.

Conducted by researchers at the University of Texas Southwestern Medical Center and the Parkland Health and Hospital System, the observational cohort study reviewed 11,309 patients discharged between November 1, 2009 and October 30, 2010 from six Texas hospitals, examining the incidence, predictors, and post-discharge outcomes associated with HAA. More...
Patients with anemia on admission or missing hematocrit values were excluded.

The results revealed that one-third of the patients developed HAA - 21.6% with mild HAA; 10.1% with moderate HAA; and 1.4% with severe HAA. The most severe form of HAA--defined as a hematocrit of 27% or less at the time of discharge--was independently associated with a 39% increase in odds of being readmitted or dying within 30 days after hospital discharge. The two strongest potentially modifiable predictors of developing moderate or severe HAA were length of stay and a major procedure. The study was published in the May 2017 issue of the Journal of Hospital Medicine.

“This is the first study of post-discharge adverse outcomes of hospital-acquired anemia among a diverse group of patients who were hospitalized for different reasons,” said lead author Anil Makam, MD, of UT Southwestern. “Reducing blood loss during major surgeries and reducing unnecessary testing during hospital stays may lower a patient's risk of developing severe hospital-acquired anemia, and potentially improve their recovery.”

“This study shines a spotlight on a very common but underappreciated risk of hospitalization, hospital-acquired anemia, which has traditionally been viewed as an incidental change in the red blood count of no significance,” said senior author Professor Ethan Halm, MD, MPH. “However, our results showed that hospital-acquired anemia was associated with worse clinical outcomes after leaving the hospital, so it needs to be taken more seriously.”

Hematocrit is the volume percentage of red blood cells (RBCs) in blood; it is normally 45% for men and 40% for women. It is considered an integral part of the complete blood count (CBC), together with hemoglobin concentration, white blood cell count, and platelet count. Anemia refers to an abnormally low hematocrit, which could indicate life-threatening diseases such as bleeding, leukemia, malnutrition, water intoxication, and more.


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.